Abiopharma

🔍 Tessari Eben (Executive)

Company: Kiniksa Pharmaceuticals International, plc (KNSA)

Report Date: 2025-09-01

Detailed Transactions and Holdings:

• Acquired 1,746 shares of Class A Ordinary Share (Direct)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 41,961.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,773 shares of Class A Ordinary Share (Direct)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 43,734.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,726 shares of Class A Ordinary Share (Direct)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 46,460.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,022 shares of Class A Ordinary Share at $33.49 per share (Direct)
  Date: 2025-09-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 43,438.00 | transaction_form_type: 4
• Acquired 1,964 shares of Class A Ordinary Share (Direct)
  Date: 2025-09-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 45,402.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 950 shares of Class A Ordinary Share at $34.28 per share (Direct)
  Date: 2025-09-02 | Code: F | equity_swap_involved: 0 | shares_owned_after: 44,452.00 | transaction_form_type: 4
• Acquired 65 shares of Class A Ordinary Share at $15.52 per share (Direct)
  Date: 2025-09-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 44,517.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 15,026 shares of Class A Ordinary Share at $15.5 per share (Direct)
  Date: 2025-09-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 59,543.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 15,091 shares of Class A Ordinary Share at $35.5 per share (Direct)
  Date: 2025-09-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 44,452.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Acquired 9,828 shares of Restricted Share Unit (Derivative)
  Date: 2025-09-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 9,828.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4
• Acquired 39,364 shares of Share Option at $33.49 per share (Derivative)
  Date: 2025-09-01 | Code: A | Expires: 2035-08-31 | equity_swap_involved: 0 | shares_owned_after: 39,364.00 | transaction_form_type: 4 | Footnotes: F5
• Acquired 1,746 shares of Restricted Share Unit (Derivative)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,235.00 | transaction_form_type: 4 | Footnotes: F1, F6, F6
• Sold 1,773 shares of Restricted Share Unit (Derivative)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,545.00 | transaction_form_type: 4 | Footnotes: F1, F7, F7
• Sold 2,726 shares of Restricted Share Unit (Derivative)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,726.00 | transaction_form_type: 4 | Footnotes: F1, F8, F8
• Sold 1,964 shares of Restricted Share Unit (Derivative)
  Date: 2025-09-02 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F9, F9
• Sold 65 shares of Share Option at $15.52 per share (Derivative)
  Date: 2025-09-03 | Code: M | Expires: 2030-03-12 | equity_swap_involved: 0 | shares_owned_after: 59,935.00 | transaction_form_type: 4 | Footnotes: F2, F10
• Sold 15,026 shares of Share Option at $15.5 per share (Derivative)
  Date: 2025-09-03 | Code: M | Expires: 2030-09-09 | equity_swap_involved: 0 | shares_owned_after: 44,974.00 | transaction_form_type: 4 | Footnotes: F2, F10

Footnotes:

• F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
• F2: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
• F3: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $35.50 and $35.53. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
• F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025.
• F5: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025.
• F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.
• F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
• F8: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
• F9: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021.
• F10: The option is fully vested and exercisable.